IO Biotech, Inc.
Pharmaceutical Preparations · COPENHAGEN
High confidence (80%)
Updated Oct 18, 2026, 12:03 AM
What is happening
Derived by rule set status-rules-2026.09.7
The company told the SEC it entered bankruptcy or receivership. Which of the two, the filing does not say.
Latest material event: IO Biotech, Inc. was delisted from its exchange (Jun 8, 2026)
Timeline
Every material event, newest first. History is never overwritten.
IO Biotech, Inc. was delisted from its exchange
Jun 8, 2026
Delisting effective
- SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001865494 IO Biotech, Inc. 333-260301 Ole Maaloes Vej 3 Copenhagen G7 DENMARK 2200 +45 2194 7856 Common Stock 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2026-06-08”
IO Biotech, Inc. reported entering bankruptcy or receivership
Mar 31, 2026
Bankruptcy or receivership reported
- SEC EDGAR — “Item 1.03 Bankruptcy or Receivership. On March 31, 2026, after considering all strategic alternatives, IO Biotech, Inc. (the Company ) ceased operations and filed a voluntary petition for relief (the Petition ) under the provisions of Chapter 7 of Title 11 of the United States Code (the Bankruptcy Code ) in the United States Bankruptcy Court for the District of Delaware (the Bankruptcy Court ). As a result of the Petition, a Chapter 7 trustee will be appointed by the Bankruptcy Court and will assume control over the assets and liabilities of the Company, effectively eliminating the authority a…”
IO Biotech, Inc. received a delisting notice from its exchange
Feb 12, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On February 12, 2026, IO Biotech, Inc. (the Company ) received notice (the Notice ) from the Listing Qualifications staff of The Nasdaq Stock Market LLC ( Nasdaq ) that the Company is not in compliance with the continued listing requirements for The Nasdaq Global Select Market because the market value of the Company s listed securities ( MVLS ) was below the minimum of $50 million for a period of 30 consecutive business days, as required by Nasdaq Listing Rule 5450(b)(2)(A) (the MVLS…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Pharmaceutical Preparations
- Subindustry
- —
- Listing
- SEC lists the ticker IOBTQ on OTC.
- SEC CIK
- 0001865494
- Website
- —
- —
- Headquarters
- COPENHAGEN
- Also known as
- —
- Legal entities
- IO Biotech, Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
IO Biotech, Inc. — Pharmaceutical Preparations (SIC 2834) — COPENHAGEN, Denmark
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
X0203 0001354457 Nasdaq Stock Market LLC 0001865494 IO Biotech, Inc. 333-260301 Ole Maaloes Vej 3 Copenhagen G7 DENMARK 2200 +45 2194 7856 Common Stock 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2026-06-08
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 1.03 Bankruptcy or Receivership. On March 31, 2026, after considering all strategic alternatives, IO Biotech, Inc. (the Company ) ceased operations and filed a voluntary petition for relief (the Petition ) under the provisions of Chapter 7 of Title 11 of the United States Code (the Bankruptcy Code ) in the United States Bankruptcy Court for the District of Delaware (the Bankruptcy Court ). As a result of the Petition, a Chapter 7 trustee will be appointed by the Bankruptcy Court and will assume control over the assets and liabilities of the Company, effectively eliminating the authority a…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On February 12, 2026, IO Biotech, Inc. (the Company ) received notice (the Notice ) from the Listing Qualifications staff of The Nasdaq Stock Market LLC ( Nasdaq ) that the Company is not in compliance with the continued listing requirements for The Nasdaq Global Select Market because the market value of the Company s listed securities ( MVLS ) was below the minimum of $50 million for a period of 30 consecutive business days, as required by Nasdaq Listing Rule 5450(b)(2)(A) (the MVLS…
View source record
Status history
Every derived status, with the rule that produced it.
- BANKRUPTCY → BANKRUPTCYSEC_BANKRUPTCY_OR_RECEIVERSHIP · Sep 18, 2026, 01:30 AM
The company told the SEC it entered bankruptcy or receivership. Which of the two, the filing does not say.
- BANKRUPTCY → BANKRUPTCYSEC_BANKRUPTCY_OR_RECEIVERSHIP · Sep 18, 2026, 01:13 AM
The company told the SEC it entered bankruptcy or receivership. Which of the two, the filing does not say.
- BANKRUPTCY → BANKRUPTCYSEC_BANKRUPTCY_OR_RECEIVERSHIP · Sep 15, 2026, 12:35 PM
The company told the SEC it entered bankruptcy or receivership. Which of the two, the filing does not say.
- BANKRUPTCY → BANKRUPTCYSEC_BANKRUPTCY_OR_RECEIVERSHIP · Sep 14, 2026, 04:47 PM
The company told the SEC it entered bankruptcy or receivership. Which of the two, the filing does not say.
- DISTRESS_SIGNAL → BANKRUPTCYSEC_BANKRUPTCY_OR_RECEIVERSHIP · Sep 8, 2026, 04:24 AM
The company told the SEC it entered bankruptcy or receivership. Which of the two, the filing does not say.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 04:09 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.